GGGonca Gül Gündem

Gonca Gül Gündem

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gonca Gül Gündem has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • C-Reactive Protein/Albumin Ratio (CAR) Predicts Early Posttransplant Complications and Survival in Allogeneic Hematopoietic Stem Cell Transplantation Recipients

    by Şeyma Yıldız, Zeynep Arzu Yegin, Gonca Gül Gündem, Sema Yaşar, Seda Çiçekli, Zübeyde Nur Özkurt, Münci Yağcı

    C reactive protein/albumin ratio (CAR) is considered as a predictor for prognosis in a variety of systemic disorders including malignancies. We aimed to investigate the potential impact of pretransplant CAR on transplant related complications and clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT). A total of 430 alloHSCT recipients [median age: 44(18–72) years; male/female: 258/172] were included in this retrospective study. Median follow-up period was 761(1-5910) days. The study population was divided into two subgroups as low- (< 0.312) and high-CAR (≥ 0.312) [AUC: 0.61 (95%CI: 0.55–0.67); p < 0.001]. The probability of overall survival (OS) was significantly lower in CARhigh group (27.7% vs. 32.1%, p < 0.001). The frequency of posttransplant early complications including Cytomeglovirus reactivation (p = 0.04), sinusoidal obstruction syndrome (p = 0.042), sepsis (p = 0.004), nephrotoxicity (p = 0.011), dialysis requirement (p = 0.001) and acute GvHD (p = 0.026) were found to be significantly higher in CARhigh group. Pretransplant CAR was shown to have a significant impact on OS (p = 0.009) in multivariate analysis. Pretransplant CAR may be a feasible and cost effective marker to predict alloHSCT outcome for better management of early transplant related toxicity and complications.

  • Clinical factors associated with autologous stem cell transplantation outcomes in multiple myeloma: upfront transplant with MEL200 remains the standard of care

    by Başak Bostankolu Değirmenci, Zeynep Arzu Yegin, Ümit Özgür Akdemir, Ali Dede, Gonca Gül Gündem, Zübeyde Nur Özkurt, Lütfiye Özlem Atay, Münci Yağcı

    Autologous stem cell transplantation (ASCT) remains the mainstay of the treatment in newly diagnosed transplant-eligible multiple myeloma (MM) patients. This retrospective study was performed to investigate the potential prognostic markers which may modify transplant course in a total of 256 ASCT recipients [median age: 58 (30–74) years; male/female: 138/118], including pretransplant (PET0) and day + 60 (PET2) PET/CT assessments and comparative analysis of melphalan (Mel) dose. Better responses with significantly higher complete response/very good partial response rates were achieved in patients who proceeded to transplant within 301 days from diagnosis (p < 0.001). Patients who had received < 1.5 lines of treatment prior to transplant had significantly higher probability of overall survival (OS) (p = 0.004) and progression-free survival (PFS) (p < 0.001). The probability of OS was significantly higher in patients with low Eastern Cooperative Oncology Group (ECOG) performance score (PS = 0–1) (p = 0.003) and HCT-Comorbidity Index (HCT-CI = 0) (p = 0.011). The number of involved areas (p = 0.028) and maximum standardized uptake value (SUVmax) (p = 0.021) in PET0 represented significant impact on OS. The probabilities of OS (p < 0.001) and PFS (p = 0.01) were significantly better with Mel200 mg/m2 conditioning compared to Mel140 mg/m2. Conditioning with Mel200 mg/m2, early and upfront ASCT and low pretransplant treatment burden were found to be significantly associated with ASCT outcome in MM patients. Despite its predictor impact on survival and prognosis, further studies are warranted to standardize PET/CT-based response assessments before being used as a guide for treatment decisions in clinical practice.